Intellia Therapeutics’ (NTLA) “Market Outperform” Rating Reiterated at Citizens Jmp

Intellia Therapeutics (NASDAQ:NTLA)‘s stock had its “market outperform” rating restated by research analysts at Citizens Jmp in a research note issued to investors on Monday,Benzinga reports. They currently have a $30.00 target price on the stock. Citizens Jmp’s price target indicates a potential upside of 122.42% from the company’s current price.

Several other research analysts have also recently weighed in on the stock. Wells Fargo & Company boosted their price target on shares of Intellia Therapeutics from $12.00 to $15.00 and gave the stock an “equal weight” rating in a report on Tuesday, March 3rd. Chardan Capital boosted their target price on Intellia Therapeutics from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, April 27th. Sanford C. Bernstein increased their price target on Intellia Therapeutics from $13.00 to $17.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. JonesTrading upgraded Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $29.00 price target on the stock in a report on Wednesday, March 4th. Finally, Wedbush reissued a “neutral” rating and issued a $12.00 price objective on shares of Intellia Therapeutics in a research report on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $20.46.

Intellia Therapeutics Stock Up 11.4%

NASDAQ NTLA traded up $1.38 on Monday, reaching $13.49. The company had a trading volume of 2,150,354 shares, compared to its average volume of 5,486,125. The company’s fifty day moving average is $13.60 and its 200 day moving average is $12.32. Intellia Therapeutics has a 52-week low of $7.95 and a 52-week high of $28.25. The stock has a market capitalization of $1.88 billion, a P/E ratio of -3.81 and a beta of 1.92.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.11. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. The firm had revenue of $15.05 million for the quarter, compared to the consensus estimate of $13.81 million. During the same period in the previous year, the firm earned ($1.10) EPS. On average, research analysts expect that Intellia Therapeutics will post -3.18 EPS for the current year.

Hedge Funds Weigh In On Intellia Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Contrarius Group Holdings Ltd increased its position in Intellia Therapeutics by 279.4% in the third quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company’s stock worth $101,719,000 after buying an additional 4,337,428 shares during the last quarter. ARK Investment Management LLC increased its holdings in Intellia Therapeutics by 19.2% in the 4th quarter. ARK Investment Management LLC now owns 14,207,324 shares of the company’s stock worth $127,724,000 after acquiring an additional 2,288,146 shares during the last quarter. Vanguard Group Inc. raised its stake in Intellia Therapeutics by 17.8% in the 4th quarter. Vanguard Group Inc. now owns 13,010,001 shares of the company’s stock valued at $116,960,000 after acquiring an additional 1,965,181 shares during the period. State Street Corp lifted its holdings in Intellia Therapeutics by 29.1% during the fourth quarter. State Street Corp now owns 6,418,836 shares of the company’s stock valued at $57,705,000 after purchasing an additional 1,447,967 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new position in Intellia Therapeutics during the first quarter worth about $17,913,000. 88.77% of the stock is owned by institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.